22. December 2010 14:41
Aesica Pharmaceuticals has acquired three European manufacturing sites from UCB.
The sites in Germany and Italy are Aesica’s first outside the UK .
Dr Robert Hardy, Chief Executive of Aesica, says the acquisitions are “strategically crucial” to establish a presence in Europe.
The expansion follows Aesica’s acquisition of R5 Pharmaceuticals in June 2010 and will complement its existing formulations capability.
“Since Aesica was founded in 2004, we have worked continually to expand and strengthen our offering, supplying our international clients from our manufacturing sites in the UK, while striving to establish a presence in key global markets,” said Dr Hardy.
“To have now secured manufacturing sites in Europe and on such a large scale, is testament to our commitment to ensuring Aesica is recognised as a leading player on the world stage.”
Aesica supplies contract development and contract manufacturing services for Formulated Products and Active Pharmaceutical Ingredients to a host of leading pharmaceutical companies and biotechnology organisations.